Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 14/20 | 0.40 |
| ▸ | IKZF3 | Q9UKT9 | 5/20 | 0.39 |
| ▸ | TNF | P01375 | 2/20 | 0.38 |
| ▸ | IL1B | P01584 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27223025 | 1.00 | CRBN (0.40) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL25370606 | 0.80 | CRBN (0.36) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL24207572 | 0.80 | CRBN (0.36) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL27231844 | 0.78 | CRBN (0.60) | CRBNDDB1IKZF3 | |
| SCHEMBL27223046 | 0.78 | CRBN (0.60) | CRBNDDB1IKZF3 | |
| SCHEMBL29799963 | 0.78 | CRBN (0.60) | CRBNDDB1IKZF3 | |
| SCHEMBL31204455 | 0.77 | CRBN (0.60) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL31341945 | 0.76 | CRBN (0.42) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL27223855 | 0.75 | CRBN (0.47) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL31204288 | 0.75 | CRBN (0.62) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165243-A1 | EGFR DEGRADERS AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2024-05-23 | — | — | US | disclosed |
| CN-116847848-A | EGFR degrading agents and methods of use | 百济神州有限公司 | 2023-10-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240165243-A1 | EGFR DEGRADERS AND METHODS OF USE | EGFR, ERBB2, ERBB3 | CRBN 167/4885DDB1 512/4885IKZF3 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.